Literature DB >> 16943794

Relationship between chronic tadalafil administration and improvement of endothelial function in men with erectile dysfunction: a pilot study.

A Aversa1, E Greco, R Bruzziches, M Pili, G Rosano, G Spera.   

Abstract

Men with erectile dysfunction (ED) frequently have a disproportionate burden of comorbid vascular disorders including atherosclerotic disease. We investigated whether scheduled tadalafil is better than on-demand (OD) in improving endothelium-dependent vasodilatation of cavernous arteries in men with ED and whether this effect is also exerted on markers of endothelial function. We did an open-label, randomized, crossover study including 20 male outclinic patients aged 18 years or older (mean age 54 years) who had at least a 3-month history of ED of any severity or etiology. Tadalafil (20 mg) on alternate days (ADs) or OD was administered for 4 weeks. Primary end points were variations of basal inflow (peak systolic velocity (PSV)) and flow-mediated dilatation (FMD) of cavernous arteries compared with baseline at penile Duplex ultrasound. Secondary end points were variations of Q13-SIEDY scores regarding morning erections and of markers of endothelial function, that is, vascular cell adhesion molecule (VCAM), intercellular cell adhesion molecule, endothelin-1 (ET-1), insulin and C-reactive protein (CRP). PSVs and FMD were higher after AD treatment when compared with OD and baseline, respectively (P=0.0001), and improvements were maintained from 2 weeks after discontinuation (P<0.005). Patients receiving tadalafil AD experienced a significant improvement of morning erections as compared to AD treatment (P<0.0001); ET1, VCAM and CRP showed a robust decrease after chronic vs OD regimes (P<0.05), with concomitant increase in insulin levels (P<0.05), without any variation in blood pressure and other laboratory parameters. Chronic but not OD tadalafil improves endothelial function with sustained effects from its discontinuation. Chronic treatment also produces a dramatic increase in morning erections, which determines better oxygenation to the penis, thus providing a rationale for vascular rehabilitation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16943794     DOI: 10.1038/sj.ijir.3901513

Source DB:  PubMed          Journal:  Int J Impot Res        ISSN: 0955-9930            Impact factor:   2.896


  30 in total

1.  Efficacy and safety of combination of tadalafil and aspirin versus tadalafil or aspirin alone in patients with vascular erectile dysfunction: a comparative randomized prospective study.

Authors:  Zeki Bayraktar; Selami Albayrak
Journal:  Int Urol Nephrol       Date:  2019-06-22       Impact factor: 2.370

Review 2.  Erectile Dysfunction in Systemic Sclerosis.

Authors:  Veronika K Jaeger; Ulrich A Walker
Journal:  Curr Rheumatol Rep       Date:  2016-08       Impact factor: 4.592

Review 3.  A critical view on cardiovascular risk in systemic sclerosis.

Authors:  Antonios Psarras; Stergios Soulaidopoulos; Alexandros Garyfallos; George Kitas; Theodoros Dimitroulas
Journal:  Rheumatol Int       Date:  2016-07-12       Impact factor: 2.631

Review 4.  PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer.

Authors:  Anindita Das; David Durrant; Fadi N Salloum; Lei Xi; Rakesh C Kukreja
Journal:  Pharmacol Ther       Date:  2014-10-31       Impact factor: 12.310

5.  Systemic and metabolic effects of PDE5-inhibitor drugs.

Authors:  Antonio Aversa
Journal:  World J Diabetes       Date:  2010-03-15

6.  Erectile dysfunction and its management in patients with diabetes mellitus.

Authors:  Giuseppe Defeudis; Daniele Gianfrilli; Chiara Di Emidio; Riccardo Pofi; Dario Tuccinardi; Andrea Palermo; Andrea Lenzi; Paolo Pozzilli
Journal:  Rev Endocr Metab Disord       Date:  2015-10-26       Impact factor: 6.514

7.  Vascular alterations and sexual function in systemic sclerosis.

Authors:  Ann Julie Impens; James R Seibold
Journal:  Int J Rheumatol       Date:  2010-08-05

8.  Sildenafil increases sympathetically mediated vascular tone in humans.

Authors:  John M Dopp; Alexei V Agapitov; Christine A Sinkey; William G Haynes; Bradley G Phillips
Journal:  Am J Hypertens       Date:  2013-02-26       Impact factor: 2.689

Review 9.  [Chronic PDE-5 inhibition in patients with erectile dysfunction: new treatment approach using once daily Tadalafil].

Authors:  H Porst; K Hell-Momeni; H Büttner
Journal:  Urologe A       Date:  2009-11       Impact factor: 0.639

Review 10.  Erectile dysfunction and heart failure: the role of phosphodiesterase type 5 inhibitors.

Authors:  H Al-Ameri; R A Kloner
Journal:  Int J Impot Res       Date:  2009-04-23       Impact factor: 2.896

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.